Skip to main content
Erschienen in: Tumor Biology 12/2015

01.12.2015 | Research Article

Antineoplastic effects of Rhodiola crenulata treatment on B16-F10 melanoma

verfasst von: Maxine C. Dudek, Kaitlyn E. Wong, Lotfi M. Bassa, Maria Carmen Mora, Jennifer Ser-Dolansky, Jean M. Henneberry, Giovanna M. Crisi, Richard B. Arenas, Sallie S. Schneider

Erschienen in: Tumor Biology | Ausgabe 12/2015

Einloggen, um Zugang zu erhalten

Abstract

Melanoma is an aggressive form of skin cancer with limited treatment options for advanced stage disease. Early detection and wide surgical excision remain the initial mode of treatment for primary tumors thus preventing metastases and leading to improved prognosis. Through this work, we have evaluated the antineoplastic effects of Rhodiola crenulata (R. crenulata) root extracts on the B16-F10 melanoma cell line, both in vitro and in vivo. We observed that R. crenulata treatment resulted in increased cell death as well as a reduction in tumor cell proliferation and migration in vitro. Additionally, we observed that R. crenulata decreased the expression of integrin β1 and vimentin and increased the expression of E-cadherin. Further, in mice treated with a topical R. crenulata-based cream therapy, tumors were more likely to have a radial growth pattern, a reduction in mitotic activity, and an increase in tumor necrosis. We also observed that mice drinking water supplemented with R. crenulata displayed a reduction of metastatic foci in disseminated models of melanoma. Collectively, these findings suggest that R. crenulata exhibits striking antitumorigenic and antimetastatic properties and that this extract may harbor potential novel adjuvant therapy for the treatment of melanoma.
Literatur
3.
Zurück zum Zitat Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg. 1970;5:902–8.CrossRef Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg. 1970;5:902–8.CrossRef
4.
Zurück zum Zitat Balch CM, Gershenwald JE, Soong S, et al. Staging and primary tumor mitotic rate. J Surg Oncol. 2011;104:379–85.CrossRefPubMed Balch CM, Gershenwald JE, Soong S, et al. Staging and primary tumor mitotic rate. J Surg Oncol. 2011;104:379–85.CrossRefPubMed
5.
Zurück zum Zitat Chin L. The genetics of malignant melanoma: lessons from mouse and man. Nat Rev Cancer. 2003;3:559–70.CrossRefPubMed Chin L. The genetics of malignant melanoma: lessons from mouse and man. Nat Rev Cancer. 2003;3:559–70.CrossRefPubMed
6.
Zurück zum Zitat Bedrosian I, Faries MB, Guerry D, et al. Incidence of sentinel node metastasis in patients with thin primary melanoma (#1 mm) with vertical growth phase. Ann Surg Oncol. 2000;7:262–7.CrossRefPubMed Bedrosian I, Faries MB, Guerry D, et al. Incidence of sentinel node metastasis in patients with thin primary melanoma (#1 mm) with vertical growth phase. Ann Surg Oncol. 2000;7:262–7.CrossRefPubMed
7.
8.
Zurück zum Zitat Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer. 2002;2:91–100.CrossRefPubMed Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer. 2002;2:91–100.CrossRefPubMed
9.
Zurück zum Zitat Rodriguez M, Aladowicz E, Lanfrancone L, et al. Tbx3 represses E-cadherin expression and enhances melanoma invasiveness. Am J Cancer Res. 2008;68:7872–81.CrossRef Rodriguez M, Aladowicz E, Lanfrancone L, et al. Tbx3 represses E-cadherin expression and enhances melanoma invasiveness. Am J Cancer Res. 2008;68:7872–81.CrossRef
10.
Zurück zum Zitat Van Roy R, Berx G. The cell-cell adhesion molecule E-cadherin. Cell Mol Life Sci. 2008;65:3756–88.CrossRefPubMed Van Roy R, Berx G. The cell-cell adhesion molecule E-cadherin. Cell Mol Life Sci. 2008;65:3756–88.CrossRefPubMed
11.
Zurück zum Zitat Rodríguez MI, Peralta-Leal A, O’Valle F, et al. PARP-1 regulates metastatic melanoma through modulation of vimentin-induced malignant transformation. PLoS Genet. 2013. doi:10.1371/journal.pgen.1003531. Rodríguez MI, Peralta-Leal A, O’Valle F, et al. PARP-1 regulates metastatic melanoma through modulation of vimentin-induced malignant transformation. PLoS Genet. 2013. doi:10.​1371/​journal.​pgen.​1003531.
12.
13.
Zurück zum Zitat Li M, Zhang B, Sun B, et al. A novel function for vimentin: the potential biomarker for predicting melanoma hematogenous metastasis. J Exp Clin Cancer Res. 2010;29:109.CrossRefPubMedPubMedCentral Li M, Zhang B, Sun B, et al. A novel function for vimentin: the potential biomarker for predicting melanoma hematogenous metastasis. J Exp Clin Cancer Res. 2010;29:109.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Burikhanov R, Sviripa VM, Hebbar N, et al. Arylquins target vimentin to trigger Par-4 secretion for tumor cell apoptosis. Nat Chem Biol. 2014;10:924–6.CrossRefPubMedPubMedCentral Burikhanov R, Sviripa VM, Hebbar N, et al. Arylquins target vimentin to trigger Par-4 secretion for tumor cell apoptosis. Nat Chem Biol. 2014;10:924–6.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Findlay VJ, Wang C, Watson DK, et al. Epithelial-to-mesenchymal transition and the cacner stem cell phenotype: insights from cancer biology with therapeutic implications for colorectal cancer. Cancer Gene Ther. 2014;21:181–7.CrossRefPubMedPubMedCentral Findlay VJ, Wang C, Watson DK, et al. Epithelial-to-mesenchymal transition and the cacner stem cell phenotype: insights from cancer biology with therapeutic implications for colorectal cancer. Cancer Gene Ther. 2014;21:181–7.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Vleminckx K, Vakaet L, Mareel M, et al. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell. 1991;66:107–19.CrossRefPubMed Vleminckx K, Vakaet L, Mareel M, et al. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell. 1991;66:107–19.CrossRefPubMed
17.
Zurück zum Zitat Qendro V, Lundgren DH, Rezaul K, et al. Large-scale proteomic characterization of melanoma expressed proteins reveals nestin and vimentin as biomarkers that can potentially distinguish melanoma subtypes. J Proteome Res. 2014;13:5031–40.CrossRefPubMed Qendro V, Lundgren DH, Rezaul K, et al. Large-scale proteomic characterization of melanoma expressed proteins reveals nestin and vimentin as biomarkers that can potentially distinguish melanoma subtypes. J Proteome Res. 2014;13:5031–40.CrossRefPubMed
18.
Zurück zum Zitat Brown RP, Gerbarg PL. The rhodiola revolution. 1st ed. Holtzbrinck Publishers; 2004. Brown RP, Gerbarg PL. The rhodiola revolution. 1st ed. Holtzbrinck Publishers; 2004.
19.
Zurück zum Zitat Darbinyan V, Aslanyan G, Amrovan E, et al. Clinical trial of Rhodiola rosea L. extract SHR-5 in the treatment of mild to moderate depression. Nord J Psychiatry. 2007;61:343–8.CrossRefPubMed Darbinyan V, Aslanyan G, Amrovan E, et al. Clinical trial of Rhodiola rosea L. extract SHR-5 in the treatment of mild to moderate depression. Nord J Psychiatry. 2007;61:343–8.CrossRefPubMed
20.
Zurück zum Zitat Dwyer AV, Whitten DL, Hawrelak JA. Herbal medicines, other than St. John’s Wort, in the treatment of depression: a systematic review. J Clin Ther. 2001;16:40–9. Dwyer AV, Whitten DL, Hawrelak JA. Herbal medicines, other than St. John’s Wort, in the treatment of depression: a systematic review. J Clin Ther. 2001;16:40–9.
21.
Zurück zum Zitat Pannossian A, Wilkman G, Sarris J. Rosenroot (Rhodiola rosea): traditional use, chemical composition, pharmacology and clinical efficacy. Phytomedicine. 2010;17:481–93.CrossRef Pannossian A, Wilkman G, Sarris J. Rosenroot (Rhodiola rosea): traditional use, chemical composition, pharmacology and clinical efficacy. Phytomedicine. 2010;17:481–93.CrossRef
22.
Zurück zum Zitat Gauger KJ, Rodríguez-Cortés A, Hartwich M, et al. Rhodiola crenulata inhibits the tumorigenic properties of invasive mammary epithelial cells with stem cell characteristics. J Med Plants Res. 2010;4:446–54. Gauger KJ, Rodríguez-Cortés A, Hartwich M, et al. Rhodiola crenulata inhibits the tumorigenic properties of invasive mammary epithelial cells with stem cell characteristics. J Med Plants Res. 2010;4:446–54.
23.
Zurück zum Zitat Tu Y, Roberts L, Schneider SS. Rhodiola crenulata induces death and inhibits growth of breast cancer cell lines. J Med Food. 2008;11:413–23.CrossRefPubMed Tu Y, Roberts L, Schneider SS. Rhodiola crenulata induces death and inhibits growth of breast cancer cell lines. J Med Food. 2008;11:413–23.CrossRefPubMed
24.
Zurück zum Zitat Liu Z, Li X, Simoneau AR, Jafari M, et al. Rhodiola rosea extracts and salidroside decrease the growth of bladder cancer cell lines via inhibition of the mTOR pathway and induction of autophagy. Mol Carcinog. 2012;51:257–67.CrossRefPubMed Liu Z, Li X, Simoneau AR, Jafari M, et al. Rhodiola rosea extracts and salidroside decrease the growth of bladder cancer cell lines via inhibition of the mTOR pathway and induction of autophagy. Mol Carcinog. 2012;51:257–67.CrossRefPubMed
25.
Zurück zum Zitat Mora MC, Bassa LM, Wong KE, et al. Rhodiola Crenulata inhibits Wnt/β-catenin signaling in glioblastoma. J Surg Res. 2015;197(2):247–55.CrossRefPubMed Mora MC, Bassa LM, Wong KE, et al. Rhodiola Crenulata inhibits Wnt/β-catenin signaling in glioblastoma. J Surg Res. 2015;197(2):247–55.CrossRefPubMed
27.
Zurück zum Zitat Motulsky HJ, Brown RE. Detecting outliers when fitting data with nonlinear regression – a new method based on robust nonlinear regression and the false discovery rate. BMC Bioinf. 2006. doi:10.1186/1471-2105-7-123. Motulsky HJ, Brown RE. Detecting outliers when fitting data with nonlinear regression – a new method based on robust nonlinear regression and the false discovery rate. BMC Bioinf. 2006. doi:10.​1186/​1471-2105-7-123.
28.
Zurück zum Zitat Skopińska-Różewska E, Hartwich M, Siwicki AK, et al. The influence of Rhodiola rosea extracts and rosavin on cutaneous angiogeneis induced in mice after grafting of syngeneic tumor cells. Cent Eur J Immunol. 2008;33:102–7. Skopińska-Różewska E, Hartwich M, Siwicki AK, et al. The influence of Rhodiola rosea extracts and rosavin on cutaneous angiogeneis induced in mice after grafting of syngeneic tumor cells. Cent Eur J Immunol. 2008;33:102–7.
29.
Zurück zum Zitat Skopińska-Różewska E, Wasiutyński A, Sommer E, et al. The infuence of Rhodiola rosea, Rhodiola kirilowii and Rhodiola quadrifida extracts on cutaneous angiogenesis induced in mice after graftin of human kidney cancer tissue. Cent Eur J Immunol. 2008;33:185–9. Skopińska-Różewska E, Wasiutyński A, Sommer E, et al. The infuence of Rhodiola rosea, Rhodiola kirilowii and Rhodiola quadrifida extracts on cutaneous angiogenesis induced in mice after graftin of human kidney cancer tissue. Cent Eur J Immunol. 2008;33:185–9.
30.
31.
Zurück zum Zitat Meier F, Satyamoorthy K, Nesbit M, et al. Molecular events in melanoma development and progression. Front Biosci. 1998;3:1005–10.CrossRef Meier F, Satyamoorthy K, Nesbit M, et al. Molecular events in melanoma development and progression. Front Biosci. 1998;3:1005–10.CrossRef
32.
Zurück zum Zitat Kuphal S, Bauer R, Bosserhoff A. Integrin signaling in malignant melanoma. Cancer Metastasis Rev. 2005;24:195–222.CrossRefPubMed Kuphal S, Bauer R, Bosserhoff A. Integrin signaling in malignant melanoma. Cancer Metastasis Rev. 2005;24:195–222.CrossRefPubMed
33.
Zurück zum Zitat Hieken TJ, Ronan SG, Farolan M, et al. Beta1 integrin expression in malignant melanoma predicts occult lymph node metastases. Surgery. 1995;118:669–73.CrossRefPubMed Hieken TJ, Ronan SG, Farolan M, et al. Beta1 integrin expression in malignant melanoma predicts occult lymph node metastases. Surgery. 1995;118:669–73.CrossRefPubMed
34.
Zurück zum Zitat Qian F, Zhang Z, Wu X, et al. Interaction between integrin α5 and fibronectin is required for metastasis of B16F10 melanoma cells. Biochem Biophys Res Commun. 2005;12:1269–75.CrossRef Qian F, Zhang Z, Wu X, et al. Interaction between integrin α5 and fibronectin is required for metastasis of B16F10 melanoma cells. Biochem Biophys Res Commun. 2005;12:1269–75.CrossRef
35.
Zurück zum Zitat Thompson JF, Soong S, Balch S, et al. Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the Multi-Institutional American Joint Committee on cancer melanoma staging database. J Clin Oncol. 2011;29:2199–205.CrossRefPubMedPubMedCentral Thompson JF, Soong S, Balch S, et al. Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the Multi-Institutional American Joint Committee on cancer melanoma staging database. J Clin Oncol. 2011;29:2199–205.CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Azzola MF, Shaw HM, Thompson JF, et al. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma. Cancer. 2003;97:1488–98.CrossRefPubMed Azzola MF, Shaw HM, Thompson JF, et al. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma. Cancer. 2003;97:1488–98.CrossRefPubMed
37.
38.
Zurück zum Zitat Francken AB, Shaw HM, Thompson JF, et al. The prognostic importance of tumor mitotic rate confirmed in 1317 patients with primary cutaneous melanoma and long follow-up. Ann Surg Oncol. 2004;11:426–33.CrossRefPubMed Francken AB, Shaw HM, Thompson JF, et al. The prognostic importance of tumor mitotic rate confirmed in 1317 patients with primary cutaneous melanoma and long follow-up. Ann Surg Oncol. 2004;11:426–33.CrossRefPubMed
39.
Zurück zum Zitat Chiang H, Chien Y, Wu C, et al. Hydroalcoholic extract of Rhodiola rosea L. (Crassulaceae) and its hydrolysate inhibit melanogenesis in B16F0 cells by regulating the CREB/MITF/tyrosinase pathway. Food Chem Toxicol. 2014;65:129–39.CrossRefPubMed Chiang H, Chien Y, Wu C, et al. Hydroalcoholic extract of Rhodiola rosea L. (Crassulaceae) and its hydrolysate inhibit melanogenesis in B16F0 cells by regulating the CREB/MITF/tyrosinase pathway. Food Chem Toxicol. 2014;65:129–39.CrossRefPubMed
40.
Zurück zum Zitat Mellado B, Gutierrez L, Castel T, et al. Prognostic significance of the detection of circulating malignant cells by reverse transcriptase polymerase chain reaction in long-term clinically disease-free melanoma patients. Clin Cancer Res. 1999;5:1843–8.PubMed Mellado B, Gutierrez L, Castel T, et al. Prognostic significance of the detection of circulating malignant cells by reverse transcriptase polymerase chain reaction in long-term clinically disease-free melanoma patients. Clin Cancer Res. 1999;5:1843–8.PubMed
41.
Zurück zum Zitat Hoon DS, Bostick P, Kuo C, et al. Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. Cancer Res. 2000;60:2253–7.PubMed Hoon DS, Bostick P, Kuo C, et al. Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. Cancer Res. 2000;60:2253–7.PubMed
Metadaten
Titel
Antineoplastic effects of Rhodiola crenulata treatment on B16-F10 melanoma
verfasst von
Maxine C. Dudek
Kaitlyn E. Wong
Lotfi M. Bassa
Maria Carmen Mora
Jennifer Ser-Dolansky
Jean M. Henneberry
Giovanna M. Crisi
Richard B. Arenas
Sallie S. Schneider
Publikationsdatum
01.12.2015
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 12/2015
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3742-2

Weitere Artikel der Ausgabe 12/2015

Tumor Biology 12/2015 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.